CAPR INVESTOR NOTICE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Capricor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements about its lead drug candidate Deramiocel. The FDA rejected the drug application after discovering undisclosed changes to the statistical analysis plan, causing Capricor's stock to plummet 64% on July 27, 2026, and an additional 36% on July 29, 2026, following an advisory committee vote against the drug's efficacy.